News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Inotuzumab ozogamicin with or without blinatumomab added to low-intensity chemotherapy
Photo: The Lancet Haematology/Twitter
May 18, 2023, 14:56

Inotuzumab ozogamicin with or without blinatumomab added to low-intensity chemotherapy

NEW: Inotuzumab ozogamicin with or without blinatumomab added to low-intensity chemotherapy showed promising activity in terms of PFS in older patients with B-cell ALL: results of a phase 2 trial

Source: The Lancet Haematology/Twitter

blinatumomab Inotuzumab ozogamicin phase 2 trial The Lancet Haematolog
Special Coverage
Science
Jan 26, 2025, 21:58
Nikolas Naleid: Excited to share our systematic review on pembrolizumab safety in GI cancers
Science
Jan 26, 2025, 21:58
David J. Benjamin: Why did sacituzumab govitecan fail in the TROPiCS-04 study for advanced urothelial carcinoma?
Science
Jan 26, 2025, 21:58
Fumiko Ladd Chino: Developing a simplified financial toxicity screening tool for use in clinical practice
Blog
Jan 26, 2025, 21:56
Wafaa M Rashed: Developing localized guidelines that reflect the continent's cultural, social and economic contexts
Blog
Jan 26, 2025, 21:56
Supriya Peshin: The most extraordinary team in GI oncology
Blog
Jan 26, 2025, 21:55
Razelle Kurzrock: Target Cancer National Molecular Tumor Board
Blog
Jan 26, 2025, 21:55
The current status of BCG and ways to accommodate the shortage
Blog
Jan 26, 2025, 21:55
Adjuvant chemotherapy vs Adjuvant CTRT in Gallbladder cancer
Blog
Jan 26, 2025, 21:55
Antonio D'Alessio: 9 year follow-up of adjuvant cell therapy for HCC at ASCOGI25
Blog
Jan 26, 2025, 17:30
Pan-RAS Inhibitor Shows Early, Deep Molecular Responses in PDAC
Blog
Jan 26, 2025, 17:23
Trisha Lal: Day 1 of ASCOGI25
Blog
Jan 26, 2025, 17:19
The role of social media in oncology presented by Prof. Gevorg Tamamyan